IO Biotech, Inc.
IOBT
$0.9799
-$0.0401-3.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.80M | 6.33M | 5.69M | 5.89M | 6.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.94M | 26.50M | 21.53M | 20.20M | 28.18M |
| Operating Income | -26.94M | -26.50M | -21.53M | -20.20M | -28.18M |
| Income Before Tax | -30.89M | -23.81M | -20.31M | -19.04M | -25.83M |
| Income Tax Expenses | 445.00K | 209.00K | 374.00K | 415.00K | 353.00K |
| Earnings from Continuing Operations | -31.33M | -24.02M | -20.69M | -19.46M | -26.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.33M | -24.02M | -20.69M | -19.46M | -26.18M |
| EBIT | -26.94M | -26.50M | -21.53M | -20.20M | -28.18M |
| EBITDA | -26.88M | -26.44M | -21.47M | -20.14M | -28.12M |
| EPS Basic | -0.48 | -0.36 | -0.31 | -0.30 | -0.40 |
| Normalized Basic EPS | -0.29 | -0.23 | -0.19 | -0.18 | -0.25 |
| EPS Diluted | -0.48 | -0.36 | -0.31 | -0.30 | -0.40 |
| Normalized Diluted EPS | -0.29 | -0.23 | -0.19 | -0.18 | -0.25 |
| Average Basic Shares Outstanding | 65.88M | 65.88M | 65.88M | 65.88M | 65.88M |
| Average Diluted Shares Outstanding | 65.88M | 65.88M | 65.88M | 65.88M | 65.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |